Date of Original Draft: Dec 15, 2024.
Special Note: The initial Bitcoin price considered for these calculations is $100,000 USD per BTC given we [had on Dec 15th, 2024] passed the psychological price benchmark.
Setting the Stage for Disruption
Biotechnology has long grappled with the high costs and uncertainty of drug development, leaving promising therapies for diseases like ALS underfunded. At Canurta, we recognize the need for a transformative approach—one that not only addresses these challenges but redefines how biotech innovation is funded.
The Satoshi Trials™ bring together the financial power of Bitcoin with the precision of adaptive medicine, creating a revolutionary framework for clinical research. By integrating financial technology into our funding strategy, we are not only accelerating ALS treatment but also laying the foundation for a resilient and scalable biotech model.
Navigating Financial Challenges for Strategic Growth
Traditional biotech funding models often rely heavily on dilutive equity raises and venture capital, which can limit long-term shareholder value. Canurta’s strategy disrupts this paradigm by leveraging Bitcoin’s growth potential as a dual-purpose asset: a secure treasury reserve and a catalyst for sustainable growth.
Through the Satoshi Trials™, Bitcoin reserves serve as collateral to fund clinical trials, while mining revenues create recurring income streams. This dual-engine model ensures Canurta has the financial strength to weather volatility, invest in R&D, and deliver exceptional value to our shareholders.
Vision 2035: Polykye™ and the Satoshi Trials™ (Bitcoin-Backed Clinical Trials)
By 2035, Canurta envisions a future where adaptive medicine has transformed not only how we treat diseases like ALS but also how we finance medical innovation. With the Polykye™ Platform at the forefront, our mission is to unlock the potential of nature-inspired molecules using advanced AI, delivering life-changing therapies faster and more efficiently than ever before.
Central to this vision are the Satoshi Trials™, a groundbreaking strategy that fuses Bitcoin’s unmatched growth potential with the life sciences. Through the strategic acquisition of Bitcoin, Canurta is building a treasury that fuels research while providing long-term financial stability. This approach allows us to redefine clinical trial funding—moving beyond traditional equity raises to a model that amplifies returns for shareholders.
We are not just conducting trials; we are creating a blueprint for a self-sustaining biotech enterprise. By leveraging Bitcoin-backed reserves and mining revenues, Canurta ensures that every milestone reached in the lab is mirrored by growth in shareholder value. Our financial strategy is designed to grow Canurta’s shareholder value significantly by 2030, with further upside as Bitcoin continues to appreciate.
This is more than a vision—it’s a roadmap to transforming how the biotech industry operates. With Bitcoin as our catalyst, adaptive medicine as our focus, and innovation as our driving force, Canurta is shaping a future where science and finance converge to achieve the extraordinary.
Bitcoin as the Catalyst for the Satoshi Trials™
Bitcoin-Driven Growth Strategy
At its core, Bitcoin is more than just a financial tool —it is a catalyst for innovation and a foundation for growth. Its decentralized nature and historical performance, with a base-case projected CAGR of 29%, make it an ideal asset for Canurta’s dual-engine strategy: leveraging Bitcoin as both a treasury reserve and a source of recurring income through mining.
The Satoshi Trials™ position Bitcoin as a transformative force in biotech financing. By integrating Bitcoin into our financial strategy, Canurta creates a resilient foundation that supports adaptive medicine development while providing unmatched value to shareholders. As Bitcoin grows in value, so does our ability to fund clinical trials, advance preclinical assets, and explore new frontiers in healthcare innovation.
Through fair value accounting, Canurta will bring transparency and stability to Bitcoin reserves, ensuring investors have a clear view of their growth. This forward-thinking approach aligns with the anticipated FASB and IFRS standards, demonstrating our commitment to innovation in both finance and science.
Initial Investment & Satoshi Trials™: To bring this vision to fruition, Canurta proposes allocating up to $34M USD into Bitcoin-Backed Clinical Trials, leveraging the transformative Satoshi Trials™ approach. This innovative strategy enables us to amplify the impact of our initial BTC investment by using it as collateral to secure additional Bitcoin exposure while simultaneously accessing liquidity to fund clinical trials. This dual benefit allows Canurta to accumulate appreciating assets and deploy operational capital.
Biotechnology Risk Mitigation: A New Paradigm
The high failure rate of drug development presents a substantial risk for any biotech company. By incorporating Bitcoin into its treasury strategy, Canurta diversifies its financial assets beyond traditional fiat reserves, which are vulnerable to inflation and devaluation. Clinical trials often span years, and Bitcoin’s unique potential for long-term appreciation during that same period provides an effective hedge against inflation and volatile capital markets. This strategic diversification is vital for Canurta, ensuring a steady and resilient stream of capital to fund the extensive R&D projects needed to drive transformative advancements in biotechnology.
Hedging Against Economic Uncertainty: Biotechnology is a capital-intensive field where financial uncertainty can often delay or derail critical research. To address these challenges, Canurta leverages Bitcoin as a hedge against economic volatility. Its decentralized nature, finite supply, and historical resilience position Bitcoin as an ideal asset for maintaining financial stability in even the most uncertain market conditions.
Over the past decade, Bitcoin has delivered consistent long-term growth, with a projected base-case CAGR of 29%. This growth trajectory enables Canurta to build a robust treasury reserve that not only funds clinical trials but also protects against potential downturns in traditional capital markets. By aligning Bitcoin’s growth with our operational strategy, Canurta ensures uninterrupted research and development, advancing the fight against ALS while safeguarding shareholder value.
Collateral for Loans: Bitcoin’s unique liquidity and accessibility allow Canurta to use its BTC reserves as collateral for operational funding, minimizing reliance on dilutive equity raises
• A 30% drop in Bitcoin price (from $100,000 USD to $70,000 USD) would raise the loan-to-value (LTV) ratio to 71.4%, requiring an additional $1.62M USD in collateral. • Canurta maintains sufficient cash reserves to mitigate such scenarios, ensuring that trials proceed without interruption.
This approach combines the stability of Bitcoin-backed financing with proactive risk management, creating a financial framework that supports transformative research while protecting shareholder interests.
Transforming Risk into Opportunity with Satoshi Trials™ Implementation
The Satoshi Trials™ represent a revolutionary framework for funding clinical research. By strategically leveraging Bitcoin as a treasury reserve and collateral asset, Canurta is transforming the traditional biotech funding model into a self-sustaining engine for growth.
Each trial within the Satoshi Trials™ framework follows these key steps:
Bitcoin Acquisition: Allocate $4.22M USD at $100,000/BTC to each countries clinical trial for CNR-401. This Bitcoin reserve becomes the financial backbone for clinical operations.
Collateralized Liquidity: Use the BTC holdings as collateral to secure operational funding, ensuring uninterrupted research and development.
Trial Execution and Milestone Alignment: Conduct trials across the United States, Australia, Canada, and the United Kingdom, achieving key clinical milestones that align with shareholder value creation.
Long-Term Reserve Growth: Retain BTC reserves as they appreciate, creating a financial foundation for future clinical programs.
This strategy not only funds ALS research but also establishes a scalable model for future adaptive medicine initiatives. The alignment of Bitcoin’s growth with clinical success ensures that Canurta delivers on its dual promise of advancing science and creating wealth for shareholders.
Transformative Impact of Bitcoin Integration
Unlocking New Financing Models
Public and Private Markets: Canurta’s Bitcoin strategy positions it as a pioneer at the intersection of biotechnology and financial innovation. By combining cutting-edge research with the transformative potential of Bitcoin, Canurta is setting a new standard for the industry.
By aligning Bitcoin’s growth with biotech milestones, Canurta is not just securing its future in adaptive medicine—it’s redefining what it means to lead in the public markets. A precedent for this approach can be seen in the case of MicroStrategy and other Bitcoin Standard Companies.
This strategy also offers a unique opportunity to attract institutional investors who are unable to hold Bitcoin directly but seek exposure through equities, including ETFs. By adopting this forward-thinking treasury model, Canurta aligns itself with cutting-edge financial practices that resonate with modern investment portfolios.
Institutional Investments: Building relationships with institutional investors fosters long-term growth partnerships that go beyond capital infusion. These partnerships provide Canurta with access to favorable financing terms and invaluable expertise in asset management and financial integration. By aligning with institutions that value innovative financial strategies, Canurta strengthens its financial resilience while positioning itself for sustained growth in both the biotechnology and investment landscapes.
Building a Resilient Foundation for Long Term R&D
Securing Leadership in Public Markets
Once Canurta transitions to public markets, its Bitcoin reserve will serve as a powerful catalyst for growth and investor confidence:
Enhance valuation: A strategically managed Bitcoin reserve showcases Canurta’s innovative financial approach, signalling foresight and leadership in leveraging cutting-edge strategies. Public market investors value companies that combine tangible financial assets with visionary growth strategies. This reserve not only strengthens Canurta’s financial foundation but also positions the company as a forward-thinking leader in both biotechnology and financial innovation.
Strengthening the balance sheet: Bitcoin integration fortifies Canurta’s balance sheet by providing a resilient hedge against economic volatility while demonstrating sound financial stewardship. The appreciation of Bitcoin’s value, coupled with Canurta’s strategic leveraging of BTC holdings, creates a robust financial foundation that bolsters the company’s market position. This approach reassures shareholders, instilling confidence in Canurta’s long-term stability and growth potential.
Capitalizing on the Bitcoin Opportunity
The timing of Canurta's Bitcoin Treasury Reserve strategy is uniquely advantageous. We stand at a pivotal moment in Bitcoin's growth cycle, highlighted by historical data tracking its value progression across halving cycles. The upcoming 2025 halving is projected to catalyze significant value appreciation, following the established trend of substantial price increases after previous halvings. This strategic entry point positions Canurta to capitalize on the anticipated upward momentum in Bitcoin’s value, aligning perfectly with our long-term financial and operational goals.
The Bitcoin Act of 2024, recently introduced in the U.S., marks a pivotal step in facilitating the adoption of Bitcoin as a treasury reserve asset for corporations. This legislative milestone underscores a growing institutional acceptance of Bitcoin and aligns seamlessly with Canurta’s strategy to leverage Bitcoin for both growth and financial resilience. By recognizing Bitcoin's utility in treasury management, the U.S. government has provided a regulatory foundation that reduces risk, ensures compliance, and instills greater confidence among stakeholders.
"The Bitcoin Act of 2024 is set to encourage U.S.-based companies to adopt Bitcoin as a reserve asset, recognizing its potential to safeguard against inflation and provide liquidity in an unpredictable financial landscape." (U.S. Senate Bill 4912)
This convergence of Bitcoin’s projected growth trajectory, increasing institutional adoption, and supportive government policy creates a rare and timely opportunity for Canurta to capitalize on Bitcoin’s next growth cycle. With legislation paving the way for wider acceptance and utility, Canurta is uniquely positioned to lead this transformative financial shift.
Fair Value Accounting and Financial Transparency
Bitcoin’s role in Canurta’s financial strategy extends beyond its growth potential—it serves as a cornerstone for transparency and innovation. The introduction of the FASB Accounting for Disclosure of Crypto Assets rule changes in December 2024, which allow fair value accounting for crypto assets, marks a pivotal moment for companies integrating Bitcoin into their operations. These changes, coupled with the anticipated alignment of IFRS 13, position Canurta as a leader in financial clarity.
Under fair value accounting, Canurta will report the market value of its Bitcoin holdings on a quarterly basis, providing investors with a transparent view of treasury performance. This approach eliminates legacy accounting models that obscured Bitcoin’s true value, ensuring that shareholders can track the growth of Canurta’s reserves alongside clinical milestones.
Anticipated IFRS alignment further strengthens Canurta’s position as a forward-thinking enterprise. By adhering to cutting-edge accounting standards, Canurta sets a new benchmark for financial innovation, aligning with global best practices while creating unmatched visibility for stakeholders.
Operational Execution: Diversified Funding and Risk Mitigation
Canurta’s strategy for financing clinical trials is built on precision, diversification, and risk management, ensuring financial stability even in volatile market conditions.
Diversification of Funds and R&D Credits
A cornerstone of this strategy is the disciplined allocation of funds, which are directed exclusively toward advancing clinical trials and R&D activities. This focus not only ensures alignment with Canurta’s mission-critical milestones but also unlocks additional financial advantages. By conducting clinical trials in jurisdictions like Australia, where R&D tax rebates of up to 43.5% are available, Canurta recoups a significant portion of its expenditures. These rebates provide a reliable cash inflow that offsets loan repayments, further reinforcing the sustainability of this strategy.
This dual-pronged approach—diversifying funds into R&D while leveraging tax incentives—creates a self-sustaining financial ecosystem. It minimizes reliance on speculative investments and external fundraising, ensuring operational continuity and advancing Canurta’s pipeline without diluting shareholder value.
Leveraging Bitcoin’s Long-Term Growth Potential
Bitcoin’s historical performance and modeled projections further solidify the viability of this strategy. Despite its short-term volatility, Bitcoin has demonstrated remarkable long-term growth, with annualized returns historically ranging between 60% and 100% over the past decade. Looking forward, the Bitcoin24 model projects a 21-year annualized growth rate (ARR) of 20.5% (Bear), 28.9% (Base), and 37.1% (Bull), positioning Bitcoin as a high-performing asset even under conservative scenarios. This robust historical track record and forward-looking projections reinforce Canurta’s strategic use of Bitcoin as a treasury reserve, enhancing the company’s financial resilience, operational stability, and ability to weather the challenges of biotech R&D.
Stress-Tested Risk Management
Canurta has prepared for adverse market conditions through extensive stress testing, ensuring the company’s financial position remains secure in a range of scenarios. Even in extreme cases, such as a 70% drop in Bitcoin’s value, Canurta’s BTC reserves are structured to withstand such volatility, with long-term value recovery anticipated. For example, a 30% price decline—from $100,000 USD to $70,000 USD—would increase the Loan-to-Value (LTV) ratio to 71.4%, requiring an additional $1.62 million USD in collateral to maintain loan terms. In more severe scenarios, such as a 50% price drop, the LTV would reach 100%, necessitating an additional $4.22 million USD in collateral. By maintaining sufficient cash reserves upfront, Canurta ensures uninterrupted operations and retains the flexibility to capitalize on market opportunities, such as acquiring additional Bitcoin at reduced prices during market downturns.
This disciplined approach to collateral management protects Canurta’s financial stability, ensuring that clinical operations proceed without interruption even in volatile market conditions.
The Living Hedge: Bitcoin as a Dynamic Safety Net for Investors
Beyond operational benefits, Canurta’s Bitcoin treasury serves as a dynamic catalyst for growth and innovation. By leveraging Bitcoin’s long-term appreciation potential alongside its liquidity, Canurta creates a self-sustaining financial model that strengthens the company’s position. This strategy not only amplifies returns through double leverage—using Bitcoin reserves to secure funding while retaining the asset’s upside—but also positions Canurta as a pioneer in financial resilience. Unlike traditional biotech investments, where risk is concentrated, Canurta’s Bitcoin holdings provide an added layer of strategic flexibility, empowering the company to weather challenges and capitalize on market opportunities from a position of strength.
The Bitcoin-Biotech Standard
This moment represents a rare and transformative opportunity to reshape not only how we fight ALS but also how we finance the future of medicine. Canurta’s visionary integration of adaptive medicine with the Satoshi Trials™ represents an unprecedented convergence of innovation, resilience, and strategic foresight. It is a bold and disruptive step toward tackling one of the most challenging diseases of our time while pioneering a revolutionary financial framework for biotechnology.
Our Bitcoin Treasury Reserve Thesis is not merely a funding mechanism—it is a redefinition of how biotechnology companies can sustain, scale, and thrive. By leveraging Bitcoin as a treasury asset, Canurta mitigates the limitations of traditional funding models, creating a self-sustaining financial engine that supports continuous R&D, ensures stability amid volatility, and positions the company at the forefront of financial and scientific innovation. This strategy exemplifies the values of adaptability and perseverance that inspired Bitcoin's inception and align seamlessly with Canurta’s mission to advance science and improve lives.
Bitcoin’s role within Canurta’s strategy extends far beyond its monetary value. It becomes the foundation of a sustainable financial model that fuels revolutionary science, adapts to global challenges, and delivers transformative change. By harnessing this dual force, Canurta is setting a new standard for how the life sciences industry approaches financial and clinical challenges, ensuring that cutting-edge research has the resources to thrive.
Institutional partners now have the opportunity to stand at the vanguard of this transformation. By supporting Canurta’s strategy, they join a journey that not only redefines biotech financing but also drives breakthroughs in adaptive medicine, offering hope and better outcomes for patients and families affected by ALS. Together, we can honor the visionary legacy of pioneers like Hal Finney, embrace bold ambitions, and deliver life-changing solutions. With your partnership, Canurta will turn today’s vision into tomorrow’s reality and work relentlessly toward a future where ALS is no longer a life sentence.
Contact Us:
Akeem Gardner | CEO & Founder | Canurta Therapeutics | akeem@canurta.com | akeem@canurta.com.au
References
[i] Canurta Platform
[ii] Effect of Cannflavins on Mitigating a Motor Neuron Disease - Akeem Gardner, LLB
[iii] Can the Fed’s rate cut change biotech’s ‘new normal’?
[iv] Bitcoin Whitepaper
[v] Bitcoin Returns vs Major Asset Classes
[vi] Crypto vs Gold
[viii] This is an initial allocation and Canurta’s Governance Body reserves the right to change this number to a more or less allocation of BTC over the life of the corporation.
[ix] B2X Loans
[xii] Fiat Money vs Commodity Money: Which is more Prone to Inflation?
[xiii] Why corporate foresight matters according to research
[xiv] The 2024 Bitcoin Halving: Analyzing Past Trends to Predict the Next Big Crypto Surge
[xv] S.4912 – BITCOIN Act of 2024
[xvi] Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60)